Barbarawi Mahmoud, Kheiri Babikir, Zayed Yazan, Gakhal Inderdeep, Al-Abdouh Ahmad, Barbarawi Owais, Rashdan Laith, Rizk Fatima, Bachuwa Ghassan, Alkotob Mohammad Luay
Department of Internal Medicine, Hurley Medical Center/Michigan State University, One Hurley Plaza, Flint, Michigan, 48503, USA.
Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA.
High Blood Press Cardiovasc Prev. 2019 Aug;26(4):283-291. doi: 10.1007/s40292-019-00325-5. Epub 2019 Jul 6.
The role of aspirin as a means of primary prevention remains controversial.
We have conducted a meta-analysis of all randomized controlled trials (RCTs) to evaluate the role of aspirin in primary prevention.
Literature search was performed via PubMed, Embase, and the Cochrane Library for all related RCTs. All-cause mortality was the primary endpoint. Secondary endpoints included major adverse cardiovascular events (MACE), myocardial infarction (MI), cardiovascular mortality, cerebrovascular events, and bleeding events. We used a random effects model to report the risk ratios (RRs) with 95% confidence intervals (CIs).
Our analysis included 17 RCTs (164,862 patients; 83,309 received aspirin and 81,744 received placebo). Our study did not demonstrate any significant reduction in all-cause mortality for patients treated with aspirin when compared with placebo (RR 0.97; 95% CI 0.93-1.01; P = 0.13). Sensitivity analysis performed by excluding healthy elderly (≥ 65) showed significant reductions in all-cause mortality in the aspirin-treated patients (RR 0.94; 95% CI 0.90-0.99; P = 0.01). There were no significant differences between both groups regarding cardiovascular mortality and cerebrovascular events (P > 0.05). However, aspirin-treated patients significantly reduced MACE and MI events (RR 0.89; 95% CI 0.85-0.93; P < 0.001 and RR 0.88; 95% CI 0.78-0.98; P = 0.02, respectively), respectively. However, aspirin was associated with a significantly higher incidence of bleeding, including major bleeding and intracranial bleeding (P < 0.001).
Aspirin use in primary prevention has resulted in a lower incidence of MACE and MI without significantly effecting cerebrovascular events. However, aspirin was associated with a higher bleeding risk. Use of aspirin as a means of primary prevention should be thoroughly discussed with patients and pursued based on the risk of cardiovascular disease while also considering bleeding risk.
阿司匹林作为一级预防手段的作用仍存在争议。
我们对所有随机对照试验(RCT)进行了荟萃分析,以评估阿司匹林在一级预防中的作用。
通过PubMed、Embase和Cochrane图书馆对所有相关RCT进行文献检索。全因死亡率是主要终点。次要终点包括主要不良心血管事件(MACE)、心肌梗死(MI)、心血管死亡率、脑血管事件和出血事件。我们使用随机效应模型报告风险比(RR)及95%置信区间(CI)。
我们的分析纳入了17项RCT(164,862例患者;83,309例接受阿司匹林治疗,81,744例接受安慰剂治疗)。与安慰剂相比,我们的研究未显示阿司匹林治疗的患者全因死亡率有任何显著降低(RR 0.97;95% CI 0.93 - 1.01;P = 0.13)。通过排除健康老年人(≥65岁)进行的敏感性分析显示,阿司匹林治疗的患者全因死亡率显著降低(RR 0.94;95% CI 0.90 - 0.99;P = 0.01)。两组在心血管死亡率和脑血管事件方面无显著差异(P > 0.05)。然而,阿司匹林治疗的患者显著降低了MACE和MI事件(RR分别为0.89;95% CI 0.85 - 0.93;P < 0.001和RR 0.88;95% CI 0.78 - 0.98;P = 0.02)。然而,阿司匹林与出血发生率显著升高相关,包括大出血和颅内出血(P < 0.001)。
在一级预防中使用阿司匹林可降低MACE和MI的发生率,而对脑血管事件无显著影响。然而,阿司匹林与较高的出血风险相关。作为一级预防手段使用阿司匹林应与患者进行充分讨论,并根据心血管疾病风险同时考虑出血风险来决定是否采用。